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302Allogeneic Hematopoietic Cell Transplantation for
Chronic Myelofibrosis in Australia and New Zealand:
Older Recipients Receiving Myeloablative Conditioning
at Increased Mortality Risk
Ian Nivison-Smith,1 Anthony J. Dodds,2 Jason Butler,3
Kenneth F. Bradstock,4 David D. F. Ma,2 Judy M. Simpson,5 Jeff Szer6This retrospective registry analysis examined predictive factors for outcome in 57 patients who underwent
allogeneic or syngeneic hematopoietic cell transplantation (HCT) for chronic myelofibrosis (CM), either pri-
mary (n 5 49) or following an antecedent condition (n 5 8), reported to the Australasian Bone Marrow
Transplant Registry (ABMTRR) between 1993 and 2005. During the 6 years 2000 to 2005, 40 HCTs were
performed for CM compared with 17 in the 7 years 1993 to 1999. Twenty-four recipients (42%) were age
50 or over at transplantation; all of these patients were transplanted after 1997, and 15 were given reduced
intensity conditioning (RIC) pretransplantation. The cumulative incidence of transplantation-related mortal-
ity was 18% at 100 days and 25% at 1 year posttransplantation. Up to 1 year posttransplantation 16 patients
died, with the most common causes being infection (n5 6) and graft-versus-host disease (GVHD) (n5 5). A
total of 27 patients survived for 3 years or longer posttransplantation. None of these patients required reg-
ular red blood cell transfusions, and of the 17 who had not had splenectomies, none had detectable spleno-
megaly. Twelve patients had no detectable bone marrow fibrosis, 7 had grade 1 fibrosis, and in 8 patients no
information was available. The overall survival (OS) probability for all patients was 72% at 1 year and 58% at
5 years posttransplantation. Patients age 50 and over who received myeloablative conditioning fared poorly,
with 1-year overall actuarial survival of 44% compared with 77% for all other patients (P5 .007). In multivar-
iate analysis, age 50 years and over at transplantation was the only significant independent unfavorable risk
factor for survival post-HCT (hazard ratio 2.71, 95% confidence interval 1.16-6.34, P5.02). This study shows
a clear increase in annual numbers of allogeneic HCT performed for CM in Australia and New Zealand in
recent years. Five-year survival was favorable compared with international studies, but for older recipients
who received myeloablative conditioning, mortality risk was elevated.
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Chronic myelofibrosis (CM) is a rare chronic
myeloproliferative disorder characterized by marrow
fibrosis, splenomegaly because of extramedullary
hematopoiesis, leukoerythroblastic blood changes,
and tear-drop deformities of red blood cells [1,2].
The primary pathogenetic mechanism is a clonal
stem cell disorder that results in ineffective erythropoi-
esis, dysplastic megakaryocyte hyperplasia, and an in-
crease in the ratio of immature granulocytes to total
granulocytes [1]. This disease has also been termed
agnogenic myeloid metaplasia [2,3] and myelofibrosis
with myeloid metaplasia [1]. Myelofibrosis may be pri-
mary or may develop following an antecedent hemato-
logic disorder such as essential thrombocythaemia or
polycythemia rubra vera [1,2].
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sis is clonal and has a stem cell origin [1]. Cellular
changes include increases in the number of stromal
cells and in the levels of extracellular matrix proteins,
increased angiogenesis, and osteosclerosis. These
changes in the microenvironment of the bone marrow
coexist with alterations in the cellular and extracellular
levels of various cytokines that have fibrogenic, angio-
genic, or osteogenic potential [1].
Many cytogenetic abnormalities are associated
with CM including 13q-; 20q-; 18; and abnormalities
of chromosomes 1, 7, and 9 [4]. The JAK2-V617F
mutation occurs in approximately 50% of patients
diagnosed with CM [5,6] and has been associated
with poorer survival in some studies, although this
association is still controversial [7]. Indicators of
poor prognosis include increased age and anemia at
diagnosis [1,8-10]. CM may undergo malignant
transformation to acute myeloid leukemia (AML) [1].
Allogeneic hematopoietic cell transplantation
(HCT) is the only potentially curative option currently
available for CM [2,11]. A number of studies have now
been published on the outcome of allogeneic HCT
for this disease [2,12-22]. In the current study,
accumulated results of 57 Australian and New
Zealand HCT for CM performed from 1993 to
2005 are reviewed, highlighting changes in activity,
similarities, and differences to published international
experience.PATIENTS AND METHODS
Study Design
Allogeneic HCT recipients were selected for this
study from the Australasian Bone Marrow Transplant
Recipient Registry (ABMTRR) database, which cap-
tures details on more than 95% of HCTs performed
in Australia and New Zealand [23]. Patient consent
for data to be recorded in the ABMTRR is obtained
by individual participating institutions. This study
was approved by the ABMTRR Steering Committee.
Patients were included if they underwent alloge-
neic or syngeneic HCT for the indication of chronic
myelofibrosis in Australia or New Zealand between
1993 and 2005, including those in whom the CM
was secondary to polycythemia rubra vera or essential
thrombocythemia. Patients transplanted for AMLwho
had progressed from CM were not included.
A detailed questionnaire was distributed to centers
in November 2006, asking for information on the
transplant donor and recipient, plus copies of pathol-
ogy documentation. The responses were reviewed
centrally for further coding by ABMTRR statistical
staff and clinicians. Patient data used in this analysis
comprised the most current information available as
of December 31, 2009.Definitions
Day of neutrophil engraftment was defined as the
first of 3 consecutive days when the blood neutrophil
count was equal to or higher than 0.5  109/L, and
day of platelet engraftment was defined as the first
day when the blood platelet count was higher than
20 109/L and there had been no platelet transfusions
in the previous 7 days. Median engraftment was calcu-
lated by cumulative incidence methods using death
without engraftment as a competing risk. Patients
and donors were considered HLA-identical if they
were matched at 6 of 6 A-, B-, and DR-loci at the
DNA level if available, otherwise the serologic level.
HLA-typing data was reported by each individual
center; information on additional HLA loci was not
available because of the retrospective nature of the
data collection.
Transplant-related mortality (TRM) was calcu-
lated as the cumulative incidence of deaths posttrans-
plantation from causes other than relapse and
persistent disease, which were treated as competing
risks. Patients were considered evaluable for engraft-
ment and acute graft-versus-host disease (aGVHD) if
they survived at least 21 days after HCT. GVHD
was classified as acute when occurring up to 100 days
posttransplantation, and chronic after this time. Grad-
ing of acute GVHD (aGVHD) was performed accord-
ing to criteria used by the Center for International
Blood and Marrow Research (CIBMTR) [24]. The
cumulative incidence of GVHD was calculated by
treating death fromcauses other thanGVHDas a com-
peting risk. Performance status at transplantation was
defined as good (Karnofsky performance scale of
80% or greater, or ECOG performance status of 0-1),
or poor otherwise. Relapse was defined as the reap-
pearance of morphologic criteria of myelofibrosis after
initial clearing of the marrow. Disease-free survival
(DFS) was defined as a continuous hematologic remis-
sion after transplantation. Overall survival (OS) was
defined as the time from transplantation to death or
last contact.
The grading of bone marrow fibrosis was per-
formed in accordance with the system developed by
Barosi et al. [25]. Marrow biopsies were taken pretrans-
plantation and at or near 3 months posttransplantation.
Patients were classified as ‘‘low,’’ ‘‘intermediate,’’ or
‘‘high’’ risk using the method of Dupriez [3]. Six of
the patients included in this study were analyzed in
a previous investigation of allogeneic HCT for CM
using reduced-intensity conditioning (RIC) at a single
institution [26].Analysis Methods and Software Used
All analyses were performed using Stata statistical
software Release 10 (Statacorp LP, College Station,
TX). Differences between groups were assessed using
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or a chi-squared test or Fisher exact test as appropriate
for categoric variables. OS and DFS were calculated
using Kaplan-Meier product limit estimates, and
differences between groups were assessed with the
log-rank test.
Multivariate Cox regression analysis was performed
to establish the significant factors affecting incidence of
aGVHD and OS. The following variables were tested
for significant effects in Cox regressions: year of trans-
plantation in 1993-1999 compared with 2000-2005, re-
cipient age (50 years and older), length of time from
diagnosis to transplantation, donor age and sex, donor
HLA compatibility, donor relationship to recipient,
stem cell source, type of pretransplantation condition-
ing, performance status at transplantation, red blood
cell transfusion dependency, splenectomy status at
transplantation and level of bone marrow fibrosis
pretransplantation.Table 1. Patient and Donor Characteristics
Variable Categories Values
Number of patients n 57
Patient sex M:F 39:18
Patient age Years: median (range) 47 (16-71)
Patient age range <40 10
40-49 23
50-59 16
60 + 8
Length of time
diagnosis–transplantation
Months: median (range) 22 (2-192)
Compounds used in prior
treatment
None 19
Hydroxyurea only 26
Hydroxyurea + other (1) 7
Other compounds (2) 5
Donor relation
and HLA match
HLA-identical sibling 39
Identical twin 4
Other relative 3
Unrelated 11RESULTS
Data for 57 patients transplanted between June
1993 and November 2005 at 15 centers (13 Australia,
2 New Zealand) were received and analyzed, repre-
senting all reported Australasian allogeneic HCT
activity for CM over this time. Six centers submitted
1 transplantation each, whereas the maximum number
at 1 center was 14. One recipient received an allogeneic
transplantation following an autograft for CM; all
others were first allogeneic transplantations. Forty-
nine patients were treated for primary myelofibrosis,
whereas 8 had antecedent conditions of essential
thrombocythemia (n 5 3) or polycythemia rubra vera
(n 5 5). During the 7 years 1993 to 1999, 17 HCTs
were performed (2.4 per year), and in the 6 years
2000 to 2005, 40 were performed (6.7 per year;
Figure 1). To put these figures in perspective, the total
combined population of Australia and New Zealand
was 21.4 million people in 1993 and 24.6 million in6 7
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Figure 1. Numbers of allogeneic HCT for chronic myelofibrosis in
Australia and New Zealand, 1992-2005, by recipient age. Numbers of
allogeneic HCT for chronic myelofibrosis have increased in recent years,
particularly from 2000.2005. Most (39, 68%) of the recipients were male
(Table 1). The median length of time from diagnosis
to transplantation was 15 months for patients age
under 50, compared with 37 months for those age 50
and above (P 5 .04), and 22 months overall. Twenty-
four recipients (42%) were age 50 or over at transplan-
tation; all of these patients were transplanted after
1997, and 15 were given RIC pretransplantation.
The majority of recipients (43, 75%) received hemato-
poietic cells from HLA-identical siblings, including
4 syngeneic (identical twin) transplants; the remaining
13 received grafts from adult volunteer unrelated
donors.
Two-thirds of the patients (39, 68%) received stem
cells collected from peripheral blood (PBSC). Twenty-
two patients were given cyclophosphamide/total body
irradiation (TBI) conditioning (Table 2); of these, 18
were age less than 50. Another 16 were given busul-
phan/cyclophosphamide (Bu/Cy); 13 of these patients
were age under 50. Seventeen patients had RIC regi-
mens; 15 of these patients were age 50 or over, and
all RIC transplantations were performed later thanDonor sex M:F 36:21
Donor age Years: median (range) 46 (26-70)
Stem cell source Marrow 17
Peripheral blood 39
Marrow + PB 1
Performance status
before conditioning
Good (Karnofsky 80+) 48
Poor (Karnofsky <80) 9
Red cell transfusion
dependency before
transplant
Dependent 29
Not dependent 22
Unknown 6
Grade of BM fibrosis
before transplantation
MF-1 9
MF-2 19
MF-3 20
Unknown 9
Dupriez score Good 25
Intermediate 18
Poor 13
Unknown 1
1 indicates busulphan, glivec, interferon, anagrelide, thioguanine; 2,
cytarabine/etoposide/daunorubicin, cytarabine/fludarabine, interferon,
oxymethalone; BM, bone marrow.
Table 2. Transplantation Characteristics
Variable Categories Values
Splenomegaly/
splenectomy
No splenomegaly or splenectomy 7
Splenomegaly, no splenectomy 21
Splenomegaly, splenectomy 29
CMV status Donor and recipient +ve 26
Donor 2ve, recipient +ve 11
Donor +ve, recipient 2ve 9
Donor and recipient 2ve 11
Pretransplantation
conditioning
Cyclophosphamide + TBI (1) 22
Busulphan + Cyclophosphamide 16
Other myeloablative (2) 2
Fludarabine + Melphalan (RIC) (3) 10
Fludarabine + TBI (RIC) (3) 4
Other RIC (3) 3
GVHD prophylaxis CSP (4) + MTX (5) 21
CSP + MTX + corticosteroids 10
CSP + MMF (6) 3
Other combinations 19
None 4
Hemoglobin level
before conditioning
Less than 100 g/L 24
100 g/L or higher 33
Nucleated cells given
(108/kg)
Median (range) 7.0 (1.2- 22.5)
CD34+ cells given
(106/kg)
Median (range) 4.9 (1.3- 23.9)
Median day of
engraftment
Neutrophils 16
Platelets 30
Adverse events
posttransplantation
Interstitial pneumonitis 2
Veno-occlusive disease 4
Hemorrhagic cystitis 4
CMV infection 7
1 indicates total body irradiation; 2, cyclophosphamide only,
LACE + ATGAM; 3, reduced-intensity conditioning; 4, cyclosporin;
5, methotrexate; 6, mycophenolate mofetil.
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tion; of these, 29 had a splenectomy.
More than one-half of recipients (31, 54%) re-
ceived cyclosporine (CSP) and methotrexate (MTX),
or these 2 compounds plus corticosteroids, as GVHD
prophylaxis (Table 2); the 4 syngeneic recipients re-
ceived no GVHD prophylaxis.
Cytogenetic abnormalities inmarrow samples were
unknown or not able to be tested for in 34 patients; an-
other 14 had no abnormalities listed. Two patients had
abnormalities involving deletions at the long arm of
chromosome 13 (13q-), 3 patients had abnormalities
involving deletions at the long arm of chromosome
20 (20q-) and 3 had abnormalities involving trisomy
at chromosome 8 (18). JAK2 mutation incidence was
not available for these patients, because this abnormal-
ity was not tested during the time frame of the study.
Forty-eight patients (84%) achieved neutrophil
engraftment posttransplantation, and the median
time was 16 days. Median time to neutrophil engraft-
ment was 15 days for PBSC recipients compared with
20 days for those who receivedmarrow grafts (P5 .08),
and 15 days for patients who had splenectomycompared with 19 days for those who had not (P5 .2).
Forty-one patients (72%) achieved platelet engraft-
ment posttransplantation, with a median time of
30 days. Rates of neutrophil and platelet engraftment
did not vary significantly between different recipient
age groups, cell doses, or presence of osteomyeloscle-
rosis at transplantation. Seven patients did not engraft
(ie, neither neutrophil nor platelet engraftment
achieved). Five of these patients died within 30 days
posttransplantation from severe immediate posttrans-
plantation complications and were thus not evaluable
for engraftment (3 from infection, 1 from interstitial
pneumonitis, 1 from hepatic veno-occlusive disease),
another died within 1 year, and the remaining patient
was recorded as alive at 3.9 years posttransplantation.
Pretransplantation, 29 (51%) patients were red
blood cell transfusion dependent, whereas by 30 days
posttransplantation this had dropped to 18 (35% of
surviving patients), and then to 7 (15% of surviving
patients) at 100 days posttransplantation. Twenty
patients had bone marrow fibrosis graded at MF-3
pretransplantation. Of these, 13 showed some im-
provement (7 to MF-2, 6 to MF-1) at 6 months post-
transplantation, whereas 1 patient remained MF-3,
MF status was not evaluable in another 2 patients be-
cause of early death, and was unknown in another 4.
Of 26 patients whose level of bone marrow fibrosis
was evaluable both before and 3 months after trans-
plantation, 15 had lower levels of fibrosis post- than
pretransplantation, in 8 the level of fibrosis remained
the same, and in 3 the level of fibrosis was worse post-
transplantation. All 3 of the patients whose fibrosis in-
creased posttransplantation had engrafted successfully,
with neutrophils and platelets recovering by day 20
posttransplantation. These 3 patients were age 40, 62,
and 63, and all had good performance status when
transplanted.
A total of 27 patients survived for 3 years or longer
posttransplantation. At or close to 3 years posttrans-
plantation, none of these patients required regular red
blood cell transfusions, and of the 17 who had not
had splenectomy, none had detectable splenomegaly.
Twelve patients had no detectable bone marrow
fibrosis, 7 had bone marrow fibrosis grade 1, and in 8
patients the level of bone marrow fibrosis was un-
known. Twenty-two patients had normal blood counts,
2 had low platelet levels, 1 had a low hemoglobin level,
and for 2 patients’ blood counts had not been recorded.
The overall cumulative incidence of aGVHD
Grade II and above was 37% at 100 days posttransplan-
tation. Recipients with donors other than HLA-
identical siblings experienced higher levels of aGVHD
Grade II1 (50% vs 33%, P 5 .08). Seven patients re-
lapsed between 160 and 560 days posttransplantation;
of these, 6 subsequently died, all within 2.2 years post-
transplantation, whereas the remaining relapsed patient
was recorded as alive 1.2 years posttransplantation. The
Table 3. Primary Cause of Death up to 1-Year Post-
transplantation
Primary cause Number
Infection 6
Graft-versus-host disease (GVHD) 5
Disease persistence/recurrence 2
Interstitial pneumonitis (IP) 1
Organ failure 1
Veno-occlusive disease (VOD) 1
Total deaths 16
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12% at 2 years posttransplantation, whereas that of
TRMwas 18% at 100 days and 25% at 1 year posttrans-
plantation. Recipients age 50 and over experienced
higher levels of TRM (38% vs 15% at 1 year, P5 .06).
The most common causes of death up to 1 year post-
transplantation were infection (n 5 6) and GVHD
(n 5 5, Table 3). There were 7 more deaths between
1 and 5 years posttransplantation; 4 of these were
from disease recurrence. None of the 4 syngeneic recip-
ients either relapsed or experienced aGVHD. At time of
analysis, 3 syngeneic recipients were alive at 5, 7, and
16 years posttransplantation, whereas 1 had died of
organ failure within the first year posttransplantation.
The median length of follow-up for surviving
patients at analysis was 6.0 years, with a minimum of
1.2 years. OS probability for the entire group was
72% at 1 year and 58% at 5 years posttransplantation,
whereas 5-year DFS was 57% (Figure 2). OS probabil-
ity was significantly higher for recipients age less than
50 at transplantation than for those age 50 and over
(79% at 2 years posttransplantation vs 45%, P 5 .02,
log-rank test). Patients conditioned with Cy and TBI
had lower OS than all other patients (59% at 2 years
posttransplantation vs 68%, P 5 .2). OS probability
was not significantly affected by stem cell source, he-
moglobin level at transplantation, year of transplanta-
tion, length of time from diagnosis to transplantation,
Dupriez Score [3], level of bone marrow fibrosis,0.
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Figure 2. Overall survival (OS) and disease-free survival (DFS) proba-
bility. At 5 years posttransplantation, OS was 58% and DFS was 57%.performance status, or red cell transfusion dependency
status at transplantation. Prior splenectomy had no ef-
fect on survival outcome in univariate survival analysis.
Of the 15 recipients age 50 or over who received
RIC, 7 had died by time of analysis and their 2-year
OS probability was 53%. In contrast, of the 9 recipi-
ents age 50 and over who hadmyeloablative condition-
ing regimens, 7 died before 3 years posttransplantation
and their 1-year OS probability was 44% compared
with 77% for all other recipients (P 5 .007). Age 50
years and over at transplantation was the only signifi-
cant independent unfavorable risk factor for both OS
post-HCT (hazard ratio [HR] 2.71, 95% confidence
interval [CI] 1.16-6.34, P 5 .02) and DFS (HR 3.00,
95% CI 1.30-6.93, P 5 .01). After allowing for age
group, the effect of RIC on OS appeared to be benefi-
cial (HR 0.45, 95% CI 0.16-1.24, P 5 .10).DISCUSSION
This study shows that allogeneic HCT is a poten-
tially curative treatment for CM, leading to long-term
remission for a relatively large proportion of patients.
The findings highlight the increased role of RIC
in HCT for CM in recent years. The annual numbers
of allogeneic HCT for CM in Australia and New
Zealand almost tripled between 1993-1999 (2.4 HCT
per year) and 2000-2005 (6.7 HCT per year). The
majority of this increase was because of older patients
who were being transplanted, most of whom received
RIC. The time from diagnosis to transplantation was
significantly longer for patients age 50 and above com-
pared with those who were younger, indicating that
physicians may have delayed transplantation of older
patients until major progression of the underlying
disease.
The age and sex of the patients in this study
(68%male, median age 46 years) were similar to those
in other major studies [2,11,12,15,21,27]. There was
a clear reduction in the posttransplantation average
level of bone marrow fibrosis and dependency on
red blood cell transfusions among the patients in
this study. Of those who survived for 3 years or
more posttransplantation, none were red blood cell
transfusion dependent, and none had a recorded
bone marrow fibrosis level .1.
TRM at 1 year posttransplantation was higher for
patients age 50 years and above (38%) than for those
age under 50 (15%, P 5 .06). The overall TRM of
25% at 1 year posttransplantation was similar to that
reported by other major studies [2,11,15,19,21,27].
In contrast, the cumulative incidence of relapse of
9% at 1 year and 12% at 2 years posttransplantation
was low compared with other large studies [15,21].
The OS probability at 5 years posttransplantation
(58%) compared favorably with that stated in studies
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40%) [21], and was lower than only that stated by
Kerbuay et al. [12] (61% at 7 years). Previous studies
have found factors that adversely affected survival,
which included hemoglobin levels of 100 g/L or less
pretransplantation and prior osteomyelosclerosis [2],
and factors associated with improved survival included
younger age at transplant, decreased morbidity score,
high platelet count at transplantation, and the use of
Bu/Cy conditioning [12]. The current analysis found
that myeloablative conditioning regimens were associ-
ated with younger age and that RIC was used almost
exclusively for patients age 50 years and over; condi-
tioning type alone did not have a significant effect on
outcome. Among the patients in this study age 50
and above, those receiving RIC regimens had similar
long-term survival to younger patients, whereas those
receiving myeloablative conditioning regimens fared
poorly. However, the only significant adverse factor
for posttransplantation survival found in multivariate
analysis in this study was patient age of 50 and above
(P 5 .02).
This analysis demonstrates favorable results for
patients transplanted for CM in Australia and New
Zealand compared with other international studies,
with similar levels of TRM to those reported by other
studies but comparatively low rates of relapse and high
overall OS. This study provides evidence that older pa-
tients transplanted for CM with RIC regimens experi-
ence better outcomes than those transplanted with
myeloablative regimens. Future research should clarify
the effect of the presence of the JAK2 mutation on
posttransplantation survival and the role of RIC in
transplantation conditioning for CM patients.ACKNOWLEDGMENTS
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